Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Diagnostic and prognostic use of bone turnover markers
Jörger M, Huober J. Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res 2012; 192:197-223.
01.01.2012Diagnostic and prognostic use of bone turnover markers
01.01.2012Recent Results Cancer Res 2012; 192:197-223
Jörger Markus, Huober Jens
Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?
Huober J, von Minckwitz G. Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?. Breast Care (Basel) 2011; 6:419-426.
15.12.2011Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?
15.12.2011Breast Care (Basel) 2011; 6:419-426
Huober Jens, von Minckwitz Gunter
A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer
Jörger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, ess s. A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer. Clin Breast Cancer 2011
02.12.2011A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer
02.12.2011Clin Breast Cancer 2011
Jörger Markus, Thürlimann Beat, Savidan Anita, Frick Harald, Bouchardy Christine, Konzelmann Isabelle, Probst-Hensch Nicole, ess silvia
Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
Huober J, Widmer I, von Rohr L, Müller A, von Moos R, Güth U, Aebi S, Rochlitz C, Baumann M, Thürlimann B. Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. Oncology 2011; 81:160-166.
28.10.2011Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
28.10.2011Oncology 2011; 81:160-166
Huober Jens, Widmer Isabelle, von Rohr Lukas, Müller Andreas, von Moos Roger, Güth Uwe, Aebi Stefan, Rochlitz Christoph, Baumann Michael, Thürlimann Beat
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Regan M, BIG 1-98 Collaborative Group, Thürlimann B, Coates A, Gelber R, Price K, Rabaglio M, Wardley A, Láng I, Smith I, Forbes J, Mauriac L, Ejlertsen B, Goldhirsch A, Giobbie-Hurder A, Neven P, International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011; 12:1101-8.
20.10.2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
20.10.2011Lancet Oncol 2011; 12:1101-8
Regan Meredith M, BIG 1-98 Collaborative Group, Thürlimann Beat, Coates Alan S, Gelber Richard D, Price Karen N, Rabaglio Manuela, Wardley Andrew, Láng István, Smith Ian, Forbes John F, Mauriac Louis, Ejlertsen Bent, Goldhirsch Aron, Giobbie-Hurder Anita, Neven Patrick, International Breast Cancer Study Group (IBCSG)
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober J, Thürlimann B, on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 2011
14.10.2011Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
14.10.2011Ann Oncol 2011
Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober Jens, Thürlimann Beat, on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial
Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. Ann Hematol 2011; 91:613-20.
29.09.2011Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial
29.09.2011Ann Hematol 2011; 91:613-20
Hitz Felicitas, Klingbiel Dirk, Omlin Aurelius, Riniker Salome, Zerz Andreas, Cerny Thomas
Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer.
Studer G, Rordorf T, Glanzmann C. Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer. Radiat Oncol 2011; 6:120.
22.09.2011Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer.
22.09.2011Radiat Oncol 2011; 6:120
Studer Gabriela, Rordorf Tamara, Glanzmann Christoph
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
Huober J, Nimmrich I, May C, Beckmann M, Baumgärtner A, Kubista E, Ragosch V, Azim H, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2011; 21:27-33.
08.09.2011Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
08.09.2011Breast 2011; 21:27-33
Huober Jens, Nimmrich I, May C, Beckmann M W, Baumgärtner A K, Kubista E, Ragosch V, Azim H A, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P A, Harbeck N
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 2011; 131:295-306.
04.09.2011The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
04.09.2011Breast Cancer Res Treat 2011; 131:295-306
Chirgwin Jacquie, Coates Alan S, Goldhirsch Aron, Regan Meredith M, Bonnefoi Hervé, Ejlertsen Bent, Thürlimann Beat, Price Karen N, Smith Ian, Sun Zhuoxin, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Impact of mammographic screening on the detection of good and poor prognosis breast cancers
Esserman L, van Leeuwen F, Linn S, Moore D, Glas A, Mook S, Retèl V, Knauer M, Rutgers E, Shieh Y, van 't Veer L. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 2011; 130:725-34.
04.09.2011Impact of mammographic screening on the detection of good and poor prognosis breast cancers
04.09.2011Breast Cancer Res Treat 2011; 130:725-34
Esserman Laura J, van Leeuwen Flora E, Linn Sabine, Moore Dan H, Glas Annuska M, Mook Stella, Retèl Valesca P, Knauer Michael, Rutgers Emiel J T, Shieh Yiwey, van 't Veer Laura J
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
Baumann K, Lück H, Vergote I, Schmalfeldt B, Huober J, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011; 123:27-32.
05.07.2011Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
05.07.2011Gynecol Oncol 2011; 123:27-32
Baumann K, Lück H J, Vergote I, Schmalfeldt B, Huober Jens, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Goldhirsch A, Wood W, Coates A, Gelber R, Thürlimann B, Senn H, Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-47.
27.06.2011Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
27.06.2011Ann Oncol 2011; 22:1736-47
Goldhirsch A, Wood W C, Coates A S, Gelber R D, Thürlimann Beat, Senn H-J, Panel members
Cervical and vaginal cancer in a woman with chronic graft-versus-host disease
Bolla D, Ruhstaller T, Diener P, Winder F, Hornung R. Cervical and vaginal cancer in a woman with chronic graft-versus-host disease. Int J Gynecol Obstet 2011; 114:159-160.
12.06.2011Cervical and vaginal cancer in a woman with chronic graft-versus-host disease
12.06.2011Int J Gynecol Obstet 2011; 114:159-160
Bolla Daniele, Ruhstaller Thomas, Diener Pierre-André, Winder Franziska, Hornung René
Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission
Mark M, Thürlimann B. Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission. Med Oncol 2011
12.06.2011Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission
12.06.2011Med Oncol 2011
Mark Michael, Thürlimann Beat
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
von Minckwitz G, Untch M, Diebold K, Tiemann K, Hoffmann G, Henschen S, Schrader I, Hanusch C, Clemens M, Just M, Dietrich K, Eidtmann H, Holms F, Solbach C, Tesch H, Huober J, Loibl S, Darb-Esfahani S, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011
12.06.2011Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
12.06.2011Breast Cancer Res Treat 2011
von Minckwitz Gunter, Untch Michael, Diebold Kurt, Tiemann Katharina, Hoffmann Gerald, Henschen Stephan, Schrader Iris, Hanusch Claus, Clemens Michael R, Just Marianne, Dietrich Klaus, Eidtmann Holger, Holms Frank, Solbach Christine, Tesch Hans, Huober Jens, Loibl Sibylle, Darb-Esfahani Silvia, Denkert Carsten
Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Regan M, Price K, Giobbie-Hurder A, Thürlimann B, Gelber R, for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 2011; 13:209.
26.05.2011Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
26.05.2011Breast Cancer Res 2011; 13:209
Regan Meredith M, Price Karen N, Giobbie-Hurder Anita, Thürlimann Beat, Gelber Richard D, for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Joly F, Huober J, Dell'Anna T, Ferrandina G, Vergote I, Reinthaller A, Vaughan M, Sugimoto A, Boman K, Donoghoe M, Fabbro M, Ray-Coquard I, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011; 122:226-32.
14.05.2011Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
14.05.2011Gynecol Oncol 2011; 122:226-32
Joly Florence, Huober Jens, Dell'Anna Tiziana, Ferrandina Gabriella, Vergote Ignace, Reinthaller Alexander, Vaughan Michelle, Sugimoto Akira, Boman Karin, Donoghoe Mark, Fabbro Michel, Ray-Coquard Isabelle, Pujade-Lauraine Eric
Pseudoangiomatous stromal hyperplasia of breast in man: a case report
Bolla D, Bolla N, Öhlschlegel C, Schoening A, Stickel J, Thürlimann B, Hornung R. Pseudoangiomatous stromal hyperplasia of breast in man: a case report. Breast J 2011; 17:311-2.
07.05.2011Pseudoangiomatous stromal hyperplasia of breast in man: a case report
07.05.2011Breast J 2011; 17:311-2
Bolla Daniele, Bolla Nicole, Öhlschlegel Christian, Schoening Andrea, Stickel Juliane, Thürlimann Beat, Hornung René
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
von Minckwitz G, Zahm D, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, du Bois A, Blohmer J, Müller B, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29:2150-7.
25.04.2011Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
25.04.2011J Clin Oncol 2011; 29:2150-7
von Minckwitz Gunter, Zahm Dirk-Michael, Khandan Fariba, Hoffmann Gerald, Gerber Bernd, Eidtmann Holger, Fend Falko, Dietel Manfred, Mehta Keyur, du Bois Andreas, Blohmer Jens Uwe, Müller Berit Maria, Loibl Sibylle, Budczies Jan, Hanusch Claus, Darb-Esfahani Silvia, Hilfrich Jörn, Weiss Erich, Huober Jens, Denkert Carsten